619 material Form 8-K filings that 507 companies we cover made with the SEC in December 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merck & Co. closed an underwritten public offering of eight series of notes on December 4, 2025, totaling $8.0 billion in principal, issued under an existing shelf registration. The filing discloses the terms and legal documents for the debt but does not state how the company plans to use the proceeds, so its effect on shareholders depends on details outside this filing.
Eight series of notes closed on December 4, 2025, ranging from $500 million floating rate notes due 2029 to $1.5 billion notes due 2055
Fixed-rate coupons range from 3.850% on the 2029 Notes to 5.700% on the 2065 Notes
Notes were issued under an indenture dated January 6, 2010, with U.S. Bank Trust National Association as trustee
General Purpose Acquisition Corp. closed its initial public offering of 23,000,000 units at $10.00 per unit on December 4, 2025, including 3,000,000 units from the full exercise of the underwriters' over-allotment option, for gross proceeds of $230 million. The company is a special purpose acquisition company formed to pursue a future business combination, and $230 million of the proceeds was placed in a trust account that generally cannot be released until a business combination or shareholder redemption.
23,000,000 units sold at $10.00 each, for gross proceeds of $230,000,000, with the offering closing December 4, 2025.
$230,000,000 placed in a trust account at J.P. Morgan Chase Bank, N.A., including $9,200,000 of the underwriters' deferred discount.
Private placement of 660,000 units at $10.00 per unit for $6,600,000, with the Sponsor buying 430,000 units and Jefferies LLC buying 230,000 units.
On December 2, 2025, Alexandros Argyros, Chele Farley, Jonathan Intrater and Warren Hosseinion were appointed as independent directors.
Celanese US Holdings LLC, a wholly owned subsidiary of Celanese Corporation, agreed on December 3, 2025 to sell $1.4 billion of senior notes through an underwriting agreement with BofA Securities, Inc. The notes add fixed-rate debt that the company must repay, and the filing does not state how the proceeds will be used.
$600 million of 7.000% Senior Notes due 2031 and $800 million of 7.375% Senior Notes due 2034
Underwriting Agreement dated December 3, 2025, with BofA Securities, Inc. as representative of the underwriters
Offering made under Form S-3 registration statement No. 333-271048, with a prospectus supplement dated December 2, 2025
An 8-K dated December 4, 2025 reports that ERP Operating Limited Partnership, the operating partnership of Equity Residential, signed a new $2.5 billion unsecured revolving credit agreement on December 3, 2025, replacing its existing $2.5 billion facility. The filing does not mention VIVMARK RESIDENTIAL or ticker VMRK, so the company named in the filing may differ from the one in the request and should be verified before relying on it.
December 3, 2025: ERP Operating LP entered a $2.5 billion unsecured revolving credit agreement with Bank of America, N.A. as administrative agent.
The new facility replaces an existing $2.5 billion revolver that was scheduled to mature October 26, 2027.
The new facility matures December 3, 2030 and allows up to $1.0 billion of additional borrowings.
Current pricing is Term SOFR or Daily Simple SOFR plus 72.5 basis points, with a facility fee of 12.5 basis points per annum; both depend on the credit rating.
S&P Global completed a private offering of $1.0 billion in senior unsecured notes on December 4, 2025, comprising $600 million of 4.250% notes due 2031 and $400 million of 4.800% notes due 2035. The company intends to use the net proceeds for general corporate purposes, which may include acquisitions, debt refinancing, or repurchases of its common stock, so the deal adds to the company's debt load.
$600 million of 4.250% Senior Notes due 2031 and $400 million of 4.800% Senior Notes due 2035 were sold.
Notes are fully and unconditionally guaranteed by Standard & Poor's Financial Services LLC on a senior unsecured basis.
Holders can require repurchase at 101% of principal plus accrued interest upon a Change of Control Triggering Event.
A registration rights agreement requires the company to pursue an exchange offer, with additional interest owed if it is not completed by the 365th day after issuance.
Baxter issued $2.0 billion of senior notes in three series due 2029, 2030 and 2035, receiving about $1.99 billion in net proceeds, and used part of the proceeds to repay its term loan credit agreement in full on December 4, 2025. The company also announced early results and pricing for cash tender offers for certain 2026 and 2027 notes, with a $600 million cap on the purchases.
Notes issued: $300 million 4.450% due 2029, $700 million 4.900% due 2030 and $1.0 billion 5.650% due 2035
Net proceeds of about $1.99 billion, before estimated offering expenses
Term loan credit agreement repaid in full on December 4, 2025
2027 notes tender offer subject to a $600 million cap and a proration factor of about 56%; $614,370,000 principal to be accepted on the Early Settlement Date of December 8, 2025
Exelon Corporation completed the sale of $1 billion in 3.25% convertible senior notes due March 15, 2029, including the full $100 million option, in a private offering. The company estimates net proceeds of about $987.5 million, which it intends to use to repay or refinance debt or for general corporate purposes, and the notes can be converted into cash, shares, or a combination of both. For shareholders, the deal adds debt and could lead to new shares if holders convert, with the initial conversion price set at about $57.11 per share, a 25% premium to the December 1, 2025 closing price.
Notes total $1 billion, including the $100 million option exercised in full, and mature March 15, 2029
Interest of 3.25% per year is payable semiannually, starting September 15, 2026
Initial conversion price is about $57.11 per share, a premium of about 25% over the December 1, 2025 last reported sale price
Estimated net proceeds are about $987.5 million before other offering expenses
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.